NcXHF

MARTINS, REYNOLDS, AND RIELY
4. Paik PK, Hasanovic A, Wang L, et al. Multiplex testing for driver mutations
in squamous cell carcinomas of the lung. J Clin Oncol. 2012;30
(suppl; abstr 7505).
5. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in
patients with ALK-positive non-small-cell lung cancer: updated results
from a phase 1 study. Lancet Oncol. 2012;13:1011-1019.
6. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged nonsmall-cell
lung cancer. N Engl J Med. 2014;371:1963-1971.
7. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens
at the time of acquired resistance to EGFR-TKI therapy in 155 patients
with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:
2240-2247.
8. Janne PA, Ramalingam SS, Yang JC-H, et al. Clinical activity of the
mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR
inhibitor-resistant non-small cell lung cancer (NSCLC). J Clin Oncol.
2014;32:5s (suppl; abstr 8009).
9. Sequist LV, Soria J-C, Gadgeel SM, et al. First-in-human evaluation of
CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of
mutations of EGFR (activating and T790M). J Clin Oncol. 2014;32:5s
(suppl; abstr 8010).
10. Drilon A, Wang L, Arcila ME, et al. Broad, hybrid capture-based nextgeneration
sequencing identifıes actionable genomic alterations in “drivernegative”
lung adenocarcinomas. Clin Cancer Res. Epub 2015 Jan 7.
11. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients
with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733-
742.
12. Hui D, Elsayem A, De la Cruz M, et al. Availability and integration of
palliative care at US cancer centers. JAMA. 2010;303:1054-1061.
13. Rabow MW, O’Riordan DL, Pantilat SZ. A statewide survey of adult and
pediatric outpatient palliative care services. J Palliat Med. 2014;17:1311-
1316.
14. Emanuel EJ, Young-Xu Y, Levinsky NG, et al. Chemotherapy use
among medicare benefıciaries at the end of life. Ann Intern Med. 2003;
138:639-643.
15. Giorgi F, Bascioni R, Brugni M, et al. Chemotherapy use at the end of
life: an analysis of the decision making process. J Clin Oncol. 2004;22:
539s-539s.
16. Murillo JR Jr, Koeller J. Chemotherapy given near the end of life by community
oncologists for advanced non-small cell lung cancer. Oncologist.
2006;11:1095-1099.
17. Neubauer MA, Taniguchi CB, Hoverman JR. Improving incidence of code
documentation through practice and discipline. J Oncol Pract. 2015. In
press.
18. Neubauer MA, Hoverman JR, Hayes J, et al. Telephone advance care
planning with Medicare patients having advanced care: Interim program
results. J Clin Oncol. 2015. In press.
19. Institute of Medicine. Dying in America: Improving Quality and Honoring
IndividualPreferencesNeartheEndofLife.http://books.nap.edu/openbook.
php?record_id18748. Accessed March 3, 2015.
20. American College of Rheumatology. National Medicare Fee Schedule.
https://www.rheumatology.org/Practice/Offıce/Medicare/Table_I_
2013_National_Medicare_Fee_Schedule. Accessed March 23, 2015.
21. American Board of Internal Medicine. Choosing Wisely. http://www.
choosingwisely.org. Accessed March 3, 2015.
22. Massarelli E, Andre F, Liu DD, et al. A retrospective analysis of the outcome
of patients who have received two prior chemotherapy regimens
including platinum and docetaxel for recurrent non-small-cell lung
cancer. Lung Cancer. 2003;39:55-61.
23. Asahina H, Sekine I, Horinouchi H, et al. Retrospective analysis of thirdline
and fourth-line chemotherapy for advanced non-small-cell lung
cancer. Clin Lung Cancer. 2012;13:39-43.
24. Younes RN, Pereira JR, Fares AL, et al. Chemotherapy beyond fırst-line
in stage IV metastatic non-small cell lung cancer. Rev Assoc Med Bras.
2011;57:686-691.
25. Chen YM, Shih JF, Fan WC, et al. Third-line or fourth-line chemotherapy
in non-small-cell lung cancer patients with relatively good performance
status. J Chin Med Assoc. 2011;74:209-214.
e418
2015 ASCO EDUCATIONAL BOOK | asco.org/edbook